Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease
Condition: Alzheimer Disease Interventions: Drug: Nilotinib BE 84mg; Drug: Nilotinib BE 112 mg; Drug: Placebo Sponsors: KeifeRx, LLC; Worldwide Clinical Trials; Life Molecular Imaging GmbH; Sun Pharmaceuticals Industries Limited Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 3, 2021 Category: Research Source Type: clinical trials
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase
Conditions: Chronic Myeloid Leukemia, Chronic Phase; Adult CML; Leukemia, Myeloid; Leukemia,Myeloid, Chronic Interventions: Drug: Asciminib; Drug: Ascimininb + Nilotinib Sponsors: Augusta University; H. Jean Khoury Cure CML Consortium Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 3, 2021 Category: Research Source Type: clinical trials
Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease
Condition: Alzheimer Disease Interventions: Drug: Nilotinib BE 84mg; Drug: Nilotinib BE 112 mg; Drug: Placebo Sponsors: KeifeRx, LLC; Worldwide Clinical Trials; Life Molecular Imaging GmbH; Sun Pharmaceuticals Industries Limited Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 3, 2021 Category: Research Source Type: clinical trials
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase
Conditions: Chronic Myeloid Leukemia, Chronic Phase; Adult CML; Leukemia, Myeloid; Leukemia,Myeloid, Chronic Interventions: Drug: Asciminib; Drug: Ascimininb + Nilotinib Sponsors: Augusta University; H. Jean Khoury Cure CML Consortium Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 3, 2021 Category: Research Source Type: clinical trials
Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease
Condition: Alzheimer Disease Interventions: Drug: Nilotinib BE 84mg; Drug: Nilotinib BE 112 mg; Drug: Placebo Sponsors: KeifeRx, LLC; Worldwide Clinical Trials; Life Molecular Imaging GmbH; Sun Pharmaceuticals Industries Limited Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 3, 2021 Category: Research Source Type: clinical trials
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase
Conditions: Chronic Myeloid Leukemia, Chronic Phase; Adult CML; Leukemia, Myeloid; Leukemia,Myeloid, Chronic Interventions: Drug: Asciminib; Drug: Ascimininb + Nilotinib Sponsors: Augusta University; H. Jean Khoury Cure CML Consortium Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 3, 2021 Category: Research Source Type: clinical trials
Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease
Condition: Alzheimer Disease Interventions: Drug: Nilotinib BE 84mg; Drug: Nilotinib BE 112 mg; Drug: Placebo Sponsors: KeifeRx, LLC; Worldwide Clinical Trials; Life Molecular Imaging GmbH; Sun Pharmaceuticals Industries Limited Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 3, 2021 Category: Research Source Type: clinical trials
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase
Conditions: Chronic Myeloid Leukemia, Chronic Phase; Adult CML; Leukemia, Myeloid; Leukemia,Myeloid, Chronic Interventions: Drug: Asciminib; Drug: Ascimininb + Nilotinib Sponsors: Augusta University; H. Jean Khoury Cure CML Consortium Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 3, 2021 Category: Research Source Type: clinical trials
Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease
Condition: Alzheimer Disease Interventions: Drug: Nilotinib BE 84mg; Drug: Nilotinib BE 112 mg; Drug: Placebo Sponsors: KeifeRx, LLC; Worldwide Clinical Trials; Life Molecular Imaging GmbH; Sun Pharmaceuticals Industries Limited Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 3, 2021 Category: Research Source Type: clinical trials
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Condition: Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive Interventions: Drug: Imatinib; Drug: Nilotinib; Drug: Bosutinib; Drug: Dasatinib; Drug: Asciminib Sponsor: Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 21, 2021 Category: Research Source Type: clinical trials
